洋 洋医汇 Generic drug intelligence
Information resource for healthcare professionals and licensed importers. Not medical advice. No direct-to-consumer sales of prescription medicines.

All molecules (32)

Every monograph includes approved indications, mechanism, standard dosing and adjustments, side effects and monitoring, the generic/biosimilar manufacturer landscape, Southeast Asian availability, and a sourced Bangladesh price table.

32 molecules

Osimertinib High demand
Originator: Tagrisso · AstraZeneca
Adjuvant therapy after tumor resection in adults with NSCLC whose tumors have EGFR exon 19 delet
from BDT 333 (US$2.71 / 80 mg) · 13manufacturers
Cancer (oncology) →
Crizotinib High demand
Originator: Xalkori · Pfizer
Treatment of adults with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplast
from BDT 350 (US$2.85 / 250 mg) · 7manufacturers
Cancer (oncology) →
Alectinib
Originator: Alecensa · Roche (Genentech in the US; originated by Chugai Pharmaceutical)
Adjuvant treatment in adult patients following tumor resection of ALK-positive non-small cell lu
from BDT 500 (US$4.07 / 150 mg) · 1manufacturers
Cancer (oncology) →
Pralsetinib
Originator: Gavreto · Discovered by Blueprint Medicines; co-commercialised with Genentech (Roche) in the US and by Roche ex-US; Blueprint regained global rights (excluding Greater China) in 2023
Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detecte
Cancer (oncology) →
Capmatinib
Originator: Tabrecta · Novartis (discovered by Incyte, licensed to Novartis in 2009)
Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation
from BDT 1,500 (US$12.21 / 200 mg) · 1manufacturers
Cancer (oncology) →
Sotorasib
Originator: Lumakras · Amgen
As a single agent: adult patients with KRAS G12C-mutated locally advanced or metastatic non-smal
from BDT 1,000 (US$8.14 / 120 mg) · 2manufacturers
Cancer (oncology) →
Lorlatinib
Originator: Lorbrena · Pfizer Inc.
Metastatic non-small cell lung cancer (NSCLC) in adults whose tumors are anaplastic lymphoma kin
from BDT 1,660 (US$13.51 / 100 mg) · 2manufacturers
Cancer (oncology) →
Bevacizumab
Originator: Avastin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
Metastatic colorectal cancer (mCRC) in combination with intravenous fluorouracil-based chemother
Cancer (oncology) →
Trastuzumab
Originator: Herceptin · Genentech, Inc. / F. Hoffmann-La Roche Ltd
Adjuvant treatment of HER2-overexpressing node-positive or node-negative (ER/PR-negative or with
Cancer (oncology) →
Palbociclib High demand
Originator: Ibrance · Pfizer Inc. (Pfizer Laboratories Div Pfizer Inc)
In combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal
from BDT 400 (US$3.26 / 125 mg) · 9manufacturers
Cancer (oncology) →
Abemaciclib
Originator: Verzenio · Eli Lilly and Company (Lilly USA, LLC)
In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant tre
from BDT 1,150 (US$9.36 / 200 mg) · 3manufacturers
Cancer (oncology) →
Olaparib High demand
Originator: Lynparza · AstraZeneca (distributed by AstraZeneca Pharmaceuticals LP); developed and commercialised in collaboration with Merck (MSD outside the US and Canada)
Maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BR
from BDT 350 (US$2.85 / 150 mg) · 9manufacturers
Cancer (oncology) →
Niraparib
Originator: Zejula · GlaxoSmithKline (GSK); originally developed by Tesaro (Tesaro UK Limited)
Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary per
from BDT 850 (US$6.92 / 100 mg) · 4manufacturers
Cancer (oncology) →
Ibrutinib High demand
Originator: Imbruvica · Pharmacyclics LLC (an AbbVie company) and Janssen Biotech, Inc. (Johnson & Johnson) - developed and commercialised jointly; US distributor of record: Pharmacyclics LLC
Adult patients with chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) - FDA
from BDT 320 (US$2.60 / 140 mg) · 8manufacturers
Cancer (oncology) →
Rituximab
Originator: Rituxan · Genentech, Inc. (a member of the Roche Group), with Biogen; Rituxan is jointly marketed by Biogen and Genentech USA in the US; MabThera is marketed by Roche
Non-Hodgkin's lymphoma (NHL): relapsed or refractory, low-grade or follicular, CD20-positive B-c
Cancer (oncology) →
Teriflunomide
Originator: Aubagio · Genzyme Corporation, a Sanofi company (US label lists Genzyme Corporation, Cambridge, MA; Sanofi markets Aubagio)
FDA: treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated synd
Immunology & rheumatology →
Adalimumab High demand
Originator: Humira · AbbVie (originally developed and marketed by Abbott Laboratories; initial U.S. approval 2002)
Rheumatoid arthritis: moderately to severely active RA in adults — reduces signs/symptoms, induc
Immunology & rheumatology →
Tofacitinib High demand
Originator: Xeljanz / Xeljanz XR · Pfizer (initial U.S. approval 2012)
Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp
from BDT 30 (US$0.24 / 5 mg) · 15manufacturers
Immunology & rheumatology →
Baricitinib
Originator: Olumiant · Eli Lilly and Company (co-developed with Incyte; initial U.S. approval 2018)
Rheumatoid arthritis: moderately to severely active RA in adults who have had an inadequate resp
from BDT 20 (US$0.16 / 2 mg) · 10manufacturers
Immunology & rheumatology →
Infliximab
Originator: Remicade · Janssen Biotech / Johnson & Johnson (originally Centocor); initial U.S. approval 1998
Crohn's disease: reducing signs and symptoms and inducing and maintaining clinical remission in
Immunology & rheumatology →
Sofosbuvir/Velpatasvir High demand
Originator: Epclusa · Gilead Sciences (Gilead Sciences Ireland UC for the EU)
US (FDA): treatment of adults and pediatric patients 3 years of age and older with chronic HCV g
from BDT 930 (US$7.57 / 400 mg+100 mg) · 8manufacturers
Antivirals (hepatitis C) →
Sitagliptin High demand
Originator: Januvia · Merck Sharp & Dohme (MSD), a subsidiary of Merck & Co., Inc.
US (FDA): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabete
from BDT 13 (US$0.11 / 50 mg) · 20manufacturers
Diabetes & metabolic →
Vildagliptin
Originator: Galvus · Novartis
EU (EMA / UK SmPC): treatment of type 2 diabetes mellitus in adults as monotherapy in patients i
from BDT 12 (US$0.10 / 50 mg) · 22manufacturers
Diabetes & metabolic →
Linagliptin
Originator: Tradjenta · Boehringer Ingelheim (marketed in the US by Boehringer Ingelheim Pharmaceuticals, Inc.; co-promoted with Eli Lilly in several markets)
US (FDA): adjunct to diet and exercise to improve glycemic control in adults with type 2 diabete
from BDT 6 (US$0.05 / 5 mg) · 39manufacturers
Diabetes & metabolic →
Dapagliflozin High demand
Originator: Forxiga · AstraZeneca (originally developed with Bristol-Myers Squibb)
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me
from BDT 10 (US$0.08 / 5 mg) · 8manufacturers
Diabetes & metabolic →
Empagliflozin High demand
Originator: Jardiance · Boehringer Ingelheim, co-marketed with Eli Lilly and Company (licensed from Boehringer Ingelheim International GmbH)
To reduce the risk of cardiovascular death and hospitalization for heart failure in adults with
from BDT 12 (US$0.10 / 10 mg) · 35manufacturers
Diabetes & metabolic →
Canagliflozin
Originator: Invokana · Janssen Pharmaceuticals (Johnson & Johnson), licensed from Mitsubishi Tanabe Pharma
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me
from BDT 40 (US$0.33 / 100 mg) · 4manufacturers
Diabetes & metabolic →
Pioglitazone
Originator: Actos; Actoplus Met and Actoplus Met XR · Takeda Pharmaceutical Company (first US approval 1999)
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes me
from BDT 5.07 (US$0.04 / 15 mg) · 15manufacturers
Diabetes & metabolic →
Liraglutide
Originator: Victoza · Novo Nordisk
As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients
Diabetes & metabolic →
Insulin Glargine High demand
Originator: Lantus · Sanofi
To improve glycemic control in adult and pediatric patients with diabetes mellitus (Lantus, US l
Diabetes & metabolic →
Insulin Degludec
Originator: Tresiba · Novo Nordisk
To improve glycemic control in adults with diabetes mellitus (US label of 2015)
Diabetes & metabolic →
Insulin Aspart
Originator: NovoRapid · Novo Nordisk
To improve glycemic control in adults and children with diabetes mellitus (NovoLog, US label)
Diabetes & metabolic →

Therapeutic areas

Cancer (oncology) · 15Immunology & rheumatology · 5Diabetes & metabolic · 11Antivirals (hepatitis C) · 1 Price index → Manufacturers →

Need a verified quotation?

Send us the molecule, strength, pack size, quantity and destination country. We reply with a batch-traceable quotation, certificates of analysis and shipping documentation.

Request a quotation

We supply licensed pharmacies, hospitals, importers and distributors — not direct-to-consumer patients.